Institute of Pharmacy and Molecular Biotechnology (IPMB), Heidelberg University, Heidelberg, Germany.
Biotechnol J. 2013 Oct;8(10):1213-20. doi: 10.1002/biot.201300121. Epub 2013 Jun 21.
Antimicrobial peptides (AMPs) represent a novel class of powerful natural antimicrobial agents. As AMPs are bactericidal, production of AMPs in recombinant bacteria is far from trivial. We report the production of Impatiens balsamina antimicrobial peptide 4 (Ib-AMP4, originally isolated from Impatiens balsamina) in Escherichia coli as a fusion protein and investigate Ib-AMP4's antimicrobial effects on human pathogens. A plasmid vector pET32a-Trx-Ib-AMP4 was constructed and transferred into E. coli. After induction, a soluble fusion protein was expressed successfully. The Ib-AMP4 peptide was obtained with a purity of over 90% after nickel affinity chromatography, ultrafiltration, enterokinase cleavage and sephadex size exclusion chromatography. For maximum activity, Ib-AMP4, which possesses two disulfide bonds, required activation with 5 μg/mL H2 O2 . Antimicrobial assays showed that Ib-AMP4 could efficiently target clinical multiresistant isolates including methicillin-resistant Staphylococcus aureus and extended-spectrum β-lactamase-producing E. coli. Time kill experiments revealed that Ib-AMP4 is bactericidal within 10 min after application. Haemolysis and cytotoxicity assays implied selectivity towards bacteria, an important prerequisite for clinical applications. Ib-AMP4 might be an interesting candidate for clinical studies involving patients with septicemia or for coating clinical devices, such as catheters. The method described here may be applicable for expression and purification of other AMPs with multiple disulfide bridges.
抗菌肽 (AMPs) 代表了一类新型的强效天然抗菌剂。由于 AMPs 具有杀菌作用,因此在重组细菌中生产 AMPs 并非易事。我们报告了在大肠杆菌中以融合蛋白形式生产报春花抗菌肽 4(Ib-AMP4,最初从报春花中分离得到),并研究了 Ib-AMP4 对人类病原体的抗菌作用。构建了质粒载体 pET32a-Trx-Ib-AMP4 并转入大肠杆菌。诱导后,成功表达了可溶性融合蛋白。镍亲和层析、超滤、肠激酶切割和葡聚糖凝胶排阻层析后,得到纯度超过 90%的 Ib-AMP4 肽。为了获得最大活性,具有两个二硫键的 Ib-AMP4 需要用 5 μg/mL H2O2 进行激活。抗菌测定表明,Ib-AMP4 可以有效靶向包括耐甲氧西林金黄色葡萄球菌和产超广谱β-内酰胺酶的大肠杆菌在内的临床多耐药分离株。时间杀伤实验表明,Ib-AMP4 在应用后 10 分钟内具有杀菌作用。溶血和细胞毒性实验表明 Ib-AMP4 对细菌具有选择性,这是临床应用的重要前提。Ib-AMP4 可能是败血症患者临床研究或涂层临床器械(如导管)的一个有趣候选物。这里描述的方法可能适用于具有多个二硫键的其他 AMPs 的表达和纯化。